Berobenatide
Stories
-
Pfizer registers Phase 3 trial of berobenatide in women with stress urinary incontinence and obesity
The study, titled VESPER-SUI, plans to enroll 900 participants and has a planned start date of November 17, 2026. It aims to learn about the safety and effectiveness of berobenatide in adult women with stress urinary incontinence and obesity or overweight.